| Style | Citing Format |
|---|---|
| MLA | Mahmoudi H, et al.. "Treatment of Pemphigus Patients in the Covid-19 Era: A Specific Focus on Rituximab." Dermatologic Therapy, vol. 33, no. 6, 2020, pp. -. |
| APA | Mahmoudi H, Tavakolpour S, Nili A, Salehi Farid A, Daneshpazhooh M, Rashidian M (2020). Treatment of Pemphigus Patients in the Covid-19 Era: A Specific Focus on Rituximab. Dermatologic Therapy, 33(6), -. |
| Chicago | Mahmoudi H, Tavakolpour S, Nili A, Salehi Farid A, Daneshpazhooh M, Rashidian M. "Treatment of Pemphigus Patients in the Covid-19 Era: A Specific Focus on Rituximab." Dermatologic Therapy 33, no. 6 (2020): -. |
| Harvard | Mahmoudi H et al. (2020) 'Treatment of Pemphigus Patients in the Covid-19 Era: A Specific Focus on Rituximab', Dermatologic Therapy, 33(6), pp. -. |
| Vancouver | Mahmoudi H, Tavakolpour S, Nili A, Salehi Farid A, Daneshpazhooh M, Rashidian M. Treatment of Pemphigus Patients in the Covid-19 Era: A Specific Focus on Rituximab. Dermatologic Therapy. 2020;33(6):-. |
| BibTex | @article{ author = {Mahmoudi H and Tavakolpour S and Nili A and Salehi Farid A and Daneshpazhooh M and Rashidian M}, title = {Treatment of Pemphigus Patients in the Covid-19 Era: A Specific Focus on Rituximab}, journal = {Dermatologic Therapy}, volume = {33}, number = {6}, pages = {-}, year = {2020} } |
| RIS | TY - JOUR AU - Mahmoudi H AU - Tavakolpour S AU - Nili A AU - Salehi Farid A AU - Daneshpazhooh M AU - Rashidian M TI - Treatment of Pemphigus Patients in the Covid-19 Era: A Specific Focus on Rituximab JO - Dermatologic Therapy VL - 33 IS - 6 SP - EP - PY - 2020 ER - |